Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2416 to 2430 of 8786 results

  1. Treprostinil diethanolamine for treating pulmonary arterial hypertension [TSID11772]

    Awaiting development Reference number: GID-TA11123 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Heart valve disease in adults

    Awaiting development Reference number: GID-QS10101 Expected publication date: TBC

    Quality standard
    Awaiting development

  3. Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source [ID1417]

    Awaiting development Reference number: GID-TA10426 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Obicetrapib and obicetrapib–ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID6519]

    In development Reference number: GID-TA11649 Expected publication date:  14 October 2026

    Technology appraisal guidance
    In development

  5. Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity [ID6441]: final draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 17 April 2026.

    Technology appraisal guidance
    In consultation

  6. Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over [ID6448]

    In development Reference number: GID-TA11564 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Topical tapinarof for treating mild to severe plaque psoriasis [ID6712]

    Awaiting development Reference number: GID-TA11951 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Tozorakimab for treating exacerbations of chronic obstructive pulmonary disease after optimised inhaled dual or triple therapy [ID6711]

    Awaiting development Reference number: GID-TA11944 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Transverse Tibial Transport

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  10. Subcutaneous olanzapine for treating schizophrenia [TSID12289]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. CT guided fibrin glue sealing of CSF leak to treat spontaneous intracranial hypotension

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  12. NEMOST growing domino for Neuromuscular early onset scoliosis with Risser 0 in first surgical intention

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  13. Stereotactic anterior cingulotomy for intractable pain

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  14. TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  15. Budesonide–glycopyrronium–formoterol fumarate for treating severe asthma in people 12 years and over TS ID 12018

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation